Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.
暂无分享,去创建一个
[1] A. Garrod. The incidence of alkaptonuria: a study in chemical individuality. 1902 [classical article] , 1902, The Yale journal of biology and medicine.
[2] D. Nebert,et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism , 1988, Nature.
[3] J. Miners,et al. Tolbutamide hydroxylation in humans: lack of bimodality in 106 healthy subjects. , 1993, Pharmacogenetics.
[4] S. Wrighton,et al. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. , 1993, Archives of biochemistry and biophysics.
[5] R. Kato,et al. cDNA and deduced amino acid sequences of human P450 IIA3 (CYP2A3). , 1989, Nucleic acids research.
[6] R. Branch,et al. Mephenytoin hydroxylation deficiency: Kinetics after repeated doses , 1984, Clinical pharmacology and therapeutics.
[7] Y. Funae,et al. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502). , 1998, Pharmacogenetics.
[8] M. Dahl. Cytochrome P450 Phenotyping/Genotyping in Patients Receiving Antipsychotics , 2002, Clinical pharmacokinetics.
[9] H. Echizen,et al. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin , 2003, The Pharmacogenomics Journal.
[10] A. Daly,et al. Pharmacogenetics of oral anticoagulants. , 2003, Pharmacogenetics.
[11] G. Shenfield,et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. , 1996, Pharmacogenetics.
[12] G. Granneman,et al. Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.
[13] M. Ingelman-Sundberg,et al. Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. , 2002, Pharmacogenetics.
[14] L. Balant,et al. Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers. , 1982, British journal of clinical pharmacology.
[15] Michael Böhm,et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol‐associated adverse effects , 2002, Clinical pharmacology and therapeutics.
[16] U. Meyer,et al. Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. , 1988, Biochemistry.
[17] T. Chang,et al. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes , 2003, The Pharmacogenomics Journal.
[18] M Heath-Chiozzi,et al. Clinical application of pharmacogenetics. , 2001, Trends in molecular medicine.
[19] M. I. Ngelman-Sundber. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy , 2001 .
[20] G R Wilkinson,et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.
[21] Zeruesenay Desta,et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. , 2003, Journal of the National Cancer Institute.
[22] M. Cronin,et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. , 2000, Journal of clinical psychopharmacology.
[23] C. Crespi,et al. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. , 1997, Pharmacogenetics.
[24] Robert L. Smith. The Paton Prize Award. The discovery of the debrisoquine hydroxylation polymorphism: scientific and clinical impact and consequences. , 2001, Toxicology.
[25] D. Flockhart,et al. Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.
[26] Zhaoqian Liu,et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19 , 2001, Clinical pharmacology and therapeutics.
[27] M. Eichelbaum,et al. Influence of the defective metabolism of sparteine on its pharmacokinetics , 1979, European Journal of Clinical Pharmacology.
[28] U. Meyer,et al. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification , 1990, The Lancet.
[29] F. Sjöqvist,et al. Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. , 1967, Life sciences.
[30] J. de Leon,et al. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. , 2003, Journal of clinical psychopharmacology.
[31] M. Dahl,et al. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. , 1997, Therapeutic drug monitoring.
[32] Teruhiko Yoshida,et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population , 2004, Human mutation.
[33] J. S. Miles,et al. Identification of the primary gene defect at the cytochrome P450 CYP2D locus , 1990, Nature.
[34] R. Weinshilboum. Inheritance and drug response. , 2003, The New England journal of medicine.
[35] B. Alexanderson,et al. Steady-state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapy , 1969, British medical journal.
[36] H. Melhus,et al. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial , 2002, Journal of hypertension.
[37] E. Oren,et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. , 2001, JAMA.
[38] S. Sindrup,et al. The pharmacogenetics of codeine hypoalgesia. , 1995, Pharmacogenetics.
[39] M. Ingelman-Sundberg,et al. Characterisation and PCR‐based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population , 1999, FEBS letters.
[40] M. Kennedy,et al. Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. , 2003, Pharmacogenetics.
[41] Shiew-Mei Huang,et al. Pharmacogenetics and Pharmacogenomics in Drug Development and Regulatory Decision Making: Report of the First FDA‐PWG‐PhRMA‐DruSafe Workshop , 2003, Journal of clinical pharmacology.
[42] Munir Pirmohamed,et al. Cytochrome P450 enzyme polymorphisms and adverse drug reactions. , 2003, Toxicology.
[43] R. Kaiser,et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] J. Goldstein,et al. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. , 2002, Pharmacogenetics.
[45] M. Oscarson. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[46] R. Krishnamoorthy,et al. Distinct phenotypes and genotypes of debrisoquine hydroxylation among Europeans and Chinese. , 1991, British journal of clinical pharmacology.
[47] A. Motulsky. Drug reactions enzymes, and biochemical genetics. , 1957, Journal of the American Medical Association.
[48] E. Dickson,et al. Genetics of Response to Proton Pump Inhibitor Therapy , 2003, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.
[49] A. Kjellin,et al. Omeprazole and CYP2C19 polymorphism: effects of long‐term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders , 2000, Alimentary pharmacology & therapeutics.
[50] F. Guengerich,et al. Cloning and sequence determination of a complementary DNA related to human liver microsomal cytochrome P-450 S-mephenytoin 4-hydroxylase. , 1987, Biochemistry.
[51] M. Relling,et al. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. , 1990, The Journal of pharmacology and experimental therapeutics.
[52] L. Maltais,et al. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. , 2004, Pharmacogenetics.
[53] J. Idle,et al. POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.
[54] M. Ingelman-Sundberg,et al. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. , 1999, Trends in pharmacological sciences.
[55] Kyoichi Ohashi,et al. Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer , 1998, Annals of Internal Medicine.
[56] L. Bertilsson,et al. LOW FREQUENCY OF SLOW DEBRISOQUINE HYDROXYLATION IN A NATIVE CHINESE POPULATION , 1987, The Lancet.
[57] L. Bertilsson,et al. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study , 2003, European Journal of Clinical Pharmacology.
[58] Zhaoqian Liu,et al. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[59] G. Discombe. Letter: Medical nemesis. , 1974, Lancet.
[60] I. Dunham,et al. Identification of the primary gene defect at the cytochrome P450 CYP2D , 1991 .
[61] Magnus Ingelman-Sundberg,et al. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.
[62] L. Bracco,et al. The relevance of alternative RNA splicing to pharmacogenomics. , 2003, Trends in biotechnology.
[63] M. Ingelman-Sundberg,et al. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. , 1994, Molecular pharmacology.
[64] M. Ingelman-Sundberg,et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine , 1993, The Lancet.
[65] L. Bertilsson,et al. 10‐hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes , 1998, Clinical pharmacology and therapeutics.
[66] Grethe Andersen,et al. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial , 1999, PAIN.
[67] J Licinio,et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response , 2004, Molecular Psychiatry.
[68] J. Benítez,et al. Genetic basis for differences in debrisoquin polymorphism between a spanish and other white populations , 1994, Clinical pharmacology and therapeutics.
[69] M. Ingelman-Sundberg,et al. DISASSOCIATION BETWEEN DEBRISOQUINE HYDROXYLATION PHENOTYPE AND GENOTYPE AMONG CHINESE , 1989, The Lancet.
[70] David L Veenstra,et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. , 2002, JAMA.
[71] M Ingelman-Sundberg,et al. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. , 1996, The Journal of pharmacology and experimental therapeutics.
[72] G R Wilkinson,et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. , 1994, Molecular pharmacology.
[73] Gray Jg,et al. LIVING AND DYING IN THE NINETEENTH CENTURY. , 1963 .
[74] M. Relling,et al. Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.
[75] R. Brosens,et al. CYP3A4, CYP3A5 and MDR‐1 Variant Alleles in The Dutch Caucasian Population , 2003 .
[76] U. Yasar,et al. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation , 2003, The Pharmacogenomics Journal.
[77] F. Vogel. Moderne Probleme der Humangenetik , 1959 .
[78] J. Miners,et al. Polymorphic hydroxylation of perhexiline in vitro. , 2003, British Journal of Clinical Pharmacology.
[79] A. Paterson,et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. , 2000, Pharmacogenetics.
[80] R. Tyndale,et al. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. , 2000, Molecular pharmacology.
[81] L. H. Snyder. Studies in Human Inheritance. IX, The Inheritance of Taste Deficiency in Man , 1932 .
[82] M. Ingelman-Sundberg,et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[83] A. Garrod. The Incidence of Alkaptonuria: A study in Chemical Individuality , 1996, Nutrition reviews.
[84] M Schwab,et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. , 2001, Pharmacogenetics.